ReLeaf Medical
ReLeaf Medical
Status
ReLeaf is a medical device startup company developing technology & devices to treat calcification related diseases. ReLeaf was founded in September 2006 by a group of experienced cardiologists and technology entrepreneurs at the Meytav technological incubator. Sector and Field of activity
Cardio-Vascular minimally invasive therapy, Aortic Valve stenosis, Calcification.
Over million Americans over the age of 65 suffer from calcific aortic stenosis. The symptomatic patients with calcific aortic stenosis (CAS) suffer from are heart failure, syncope, and angina. To date, surgical replacement of the aortic valve (AVR) is the only treatment for symptomatic disease. In the U.S. alone over 50,000 patients per year undergo AVR. This number represents represents less than a 1/3 of patients requiring surgery. Approximately 150,000 patients requiring AVR are not treated. Reasons for not undergoing AVR include: patient’s refusal, various co-morbidities, and risk to performing the operation. ReLeaf procedure offers these patenits a minimally invasive, catheter-based treatment which is less traumatic than AVR, and can be performed in high risk patients. Additional applications include removal of plaque from atherosclerotic arteries in peripheral arterial disease. Management
Mr. Nir Eliaz – R&D manager
Advisory Board
Dr. Renu Virmani, MD
Dr. Robert Wilenski, MD
Dr. Emile Mohler, MD
Dr. Johan Bosman, MD
Dr. Dan Aravot, MD
Dr. Laurence Shaw, MD
Dr. Avinoam Shiran, MD Board Of Directors
Dr. Moshe Y. Flugelman, MD.
Dr. Yael Nir, MD
Dr. Benny Zeevi, MD
Mr. Tomer KarivIntellectual property status
PCT patent application with priority date 2/2006
IP Pipeline of new patent applications Investment sought
The company is seeking investment in order to accelerate product development.
|
